Cart
sales@molnova.com
Dihydroberberine
CAS No. 483-15-8
Dihydroberberine( —— )
Catalog No. M21509 CAS No. 483-15-8
Dihydroberberine has anti-atherosclerotic anti-inflammatory hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 92 | In Stock |
|
| 10MG | 163 | In Stock |
|
| 25MG | 306 | In Stock |
|
| 50MG | 423 | In Stock |
|
| 100MG | 576 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDihydroberberine
-
NoteResearch use only, not for human use.
-
Brief DescriptionDihydroberberine has anti-atherosclerotic anti-inflammatory hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.
-
DescriptionDihydroberberine has anti-atherosclerotic anti-inflammatory hypolipidemic and antitumor activities. It inhibits human ether-a-go-go-related gene (hERG) channels and remarkably reduces Hsp90 expression and its interaction with hERG.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorhERG| HSP90
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number483-15-8
-
Formula Weight337.4
-
Molecular FormulaC20H19NO4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 20 mg/mL (59.28 mM)
-
SMILESCOc(ccc1c2CN(CCc(c3c4)cc5c4OCO5)C3=C1)c2OC
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Yu D et al. Inhibitory effects and mechanism of dihydroberberine on hERG channels expressed in HEK293 cells. PLoS One. 2017 Aug 1;12(8):e0181823.
molnova catalog
related products
-
Epertinib
Epertinib (S-222611) is a novel potent, orally active, reversible EGFR and HER2 inhibitor with IC50 of 1.48, 7.15 and 2.49 nM for EGFR, HER2 and HER4, respectively.
-
Matuzumab
Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in malignancy facilitating tumor growth and survival.
-
WZ4002
WZ4002 is a novel, mutant-selective EGFR inhibitor for EGFR(L858R)/(T790M) with IC50 of 2 nM/8 nM.
